<DOC>
	<DOC>NCT01110902</DOC>
	<brief_summary>The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder. This study includes an 8-week double-blind phase.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Patients with diagnosis of MDD, single or recurrent episode, according to DSMIV criteria. Current episode ≥4 weeks. CGISeverity score ≥4 at Screening and Baseline. History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder (current or during previous one year), obsessivecompulsive disorder. Any other current Axis I disorder other than MDD which is the focus of treatment. Substance or alcohol abuse in the last 30 days, dependence in the last 6 months. Concomitant psychotropic medication, including herbal preparations and melatonin. Psychotherapy of any type. Prior exposure to agomelatine. Female patients of childbearing potential who are not using effective contraception. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Agomelatine</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>depression</keyword>
</DOC>